Marc is founder of BioVersys AG, a multi-award winning biopharmaceutical company focused on combatting antimicrobial resistance. Prior to BioVersys, he completed his studies in Biology at the University of Freiburg (Germany) and the University of Queensland (Australia). He holds a PhD in Biotechnology from the ETH Zurich. Marc gained additional business experience as Associate Intern at McKinsey & Company and insights to intellectual property rights at the patent offices Ernest T. Freylinger SA (Luxemburg) and Joachim Stuercken GmbH (Germany). Marc is winner of two Venture Leaders awards (2008 and 2016) and he is Vice President of the Board of the BEAM Alliance.
Dr. Sergio Lociuro
Sergio received his Laurea degree in Chemistry at the University of Rome, Italy in 1981 and, after a two-year postdoctoral fellowship at the Italian Research National Countil, he moved t o UNB, Canada, where he received his Ph.D in 1987. In the same year he started his career in the pharmaceutical industry as a medicinal chemist. In his almost 30 years experience in major pharmaceutical companies and SMEs, Sergio has held positions such as Director of Medicinal Chemistry and International Project Leader in GSK, Head of Peptide Epitope Mimetics in Polyphor Ltd and Head of Research and Scientific Communication in Arpida AG and has been part of the Board of Directors of Arpida A/S. Founder of THOT consulting Sagl, a Swiss consulting firm providing services in the Research and Development of anti-infectives and pharmaceutical drugs in general, he has lately held the position of CSO in C10 Pharma and Adenium Biotech, two Scandinavian biotech companies. His background spans from early drug discovery to late preclinical development. He has conducted Phase I clinical studies, participated in late clinical studies and in discussions with both the US FDA and EMA.
Dr. Peter Sennhenn
Peter has a track record of more than 18 years of industrial experience in drug discovery where he successfully managed a broad range of preclinical research programs and coordinated international project teams. Before joining BioVersys, he held positions as a lab head and subsequently group leader in medicinal chemistry at Boehringer Ingelheim in Germany and Austria, as director medicinal chemistry at GPC Biotech and head of medicinal chemistry at Proteros in Martinsried, Germany and just recently as consultant in translational medicinal chemistry. His key expertise is in the area of structure based drug design, lead identification and multidimensional lead optimization, with a strong background in organic synthesis. Peter obtained his PhD in organic chemistry from the University of Heidelberg, Germany under the supervision of Prof. Günter Helmchen. He was visiting scientist in Andrew Holmes´ group at University of Cambridge, UK and conducted post-doctoral research at The Scripps Research Institute, La Jolla with K. Barry Sharpless.